Unicycive Therapeutics Competitors and Similar CompaniesClear all
Unicycive Therapeutics's competitors and similar companies include Dr Lal PathLabs, ImmusanT, Chinook Therapeutics and Mesoblast.
 Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company that develops treatment for kidney diseases with significant unmet medical needs. |  Dr Lal PathLabs Dr Lal PathLabs is an international service provider of diagnostic and related healthcare tests. |  ImmusanT ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. |  Chinook Therapeutics Chinook Therapeutics is a biopharmaceutical company that develops precision medicines for kidney diseases. |  Mesoblast Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. | |
Founding Date | Founding Date 2016 | Founding Date 1949 | Founding Date 2010 | Founding Date 2011 | Founding Date 2004 |
Type | Type Public | Type Public | Type Private | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Los Altos, US HQ | Locations Gurugram, IN HQ | Locations Cambridge, US HQ | Locations Seattle, US HQ | Locations Melbourne, AU HQ Singapore, SG New York, US |
Employees | Employees 1 | Employees 4,099 | Employees 2 | Employees 27 | Employees 73 |
Valuation ($) | Valuation ($) 45.5 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ₹27.6b (FY, 2026) | Revenue (est.) N/A | Revenue (est.) $6.1m (FY, 2022) | Revenue (est.) $17.2m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods ₹5.3b (FY, 2026) | Cost of goods N/A | Cost of goods N/A | Cost of goods $1.2m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit ₹23.3b (FY, 2026) | Gross profit N/A | Gross profit N/A | Gross profit $16.1m (FY, 2025) |
Net income | Net income N/A | Net income ₹5.1b (FY, 2026) | Net income N/A | Net income ($187.9m) (FY, 2022) | Net income ($102.1m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 72.8m | Total funding raised $ 171m | Total funding raised $ 56.2m |
For sources of this data, please see the company profile
View Company Profiles
Dr Lal PathLabs
HQ
Gurugram, IN
Employees
4,099
Dr Lal PathLabs is an international service provider of diagnostic and related healthcare tests.
View companyImmusanT
HQ
Cambridge, US
Employees
2
ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases.
View companyChinook Therapeutics
HQ
Seattle, US
Chinook Therapeutics is a biopharmaceutical company that develops precision medicines for kidney diseases.
View companyMesoblast
HQ
Melbourne, AU
Employees
73
Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine.
View company